<DOC>
	<DOC>NCT00920725</DOC>
	<brief_summary>The purpose of this study is to determine whether insulin administered by a subcutaneous injection is effective in the treatment of a diabetic crisis and to determine if beta-hydroxybutyrate is useful to monitor during treatment of a diabetic crisis.</brief_summary>
	<brief_title>Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA</brief_title>
	<detailed_description />
	<mesh_term>Ketosis</mesh_term>
	<mesh_term>Acidosis</mesh_term>
	<mesh_term>Diabetic Ketoacidosis</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>age 18 or older venous pH &lt; 7.3 or arterial &lt; 7.35 at least 2 of the following 3: 1. serum HCO3 &lt; 18/anion gap &gt; 16 2. serum glucose &gt; 300 mg/dl 3. serum acetone positive pregnant less than age 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>DKA</keyword>
</DOC>